First human trial targets aging immune cells for healthier immunity

UCL scientists, via biotech SenTcell founded by Dr Alessio Lanna, plan a first-in-human Phase 1 trial later this year of an immune rejuvenation therapy to restore exhausted or senescent T cells. The intramuscular liquid aims to metabolically reprogramme CD4+ T cells. The MHRA ILAP has backed the programme. Phase 1 will assess safety and biological activity in adults with immune dysfunction.

Original reporting
Published Jun 18, 2026, 2:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 18, 2026, 2:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
First human trial targets aging immune cells for healthier immunity — source image
Decision brief

The 30-second read

Low
01

Why it matters

The only concrete new facts are that a Phase 1 trial is expected to start later this year and that the program received MHRA ILAP support; the trial’s primary goals are safety and biological activity, not clinical efficacy.

02

Market read

This is an early-stage clinical development update with regulatory-pathway support, but it does not provide a publicly listed company identifier or tradable financial/regulatory milestone.

03

What to watch

Key tradable details are missing (company name/ticker, IND/ethics approvals, trial site, enrollment size, endpoints, funding/partnering). Without these, risk/reward for public equities can’t be repriced reliably.

Relevance 3/10Novelty 3/10Timing: trial expected to begin later this year; Phase 1 planning described

Background

The article describes a first-in-human Phase 1 immune rejuvenation program targeting exhausted/senescent T cells, building on UCL research into immune aging and telomere-related mechanisms.

Market effects

Highlights ongoing immune-rejuvenation R&D and MHRA ILAP support for immune-aging indications, but no specific public-market company catalyst is disclosed.

UK regulatory pathway support (MHRA ILAP) may modestly reinforce sentiment toward UK/Europe immunology innovation, without naming a listed issuer.

If validated, the approach could broaden the immune-aging treatment landscape (cancer/HIV/dementia), but the article provides no tradable company-specific milestones.

Counterpoint

Because the therapy is described at a conceptual/Phase 1 planning level with no trial results, any near-term market impact on public biotech is likely limited until dosing/safety data emerge.

Key entities

  • SenTcell

    Developed the immune rejuvenation therapy; founded by Dr Alessio Lanna (UCL Medicine).

  • UCL Medicine

    Led underlying research into immune aging mechanisms and telomere-related hypotheses.

  • MHRA ILAP

    Provided support via the Innovative Licensing and Access Pathway for the immune-aging program.

Related articles

$VERUMed

Veru presents data on enobosarm for obesity treatment

Veru Inc. (VERU) presented Phase 2b QUALITY study data at ObesityWeek 2026, showing enobosarm 3mg plus semaglutide helped patients aged 65+ with obesity gain lean mass and maintain physical function. The Phase 2b PLATEAU trial, with 239 patients, is ongoing, with interim data expected in Q1 2027. Veru has a clinical supply agreement with Novo Nordisk and a U.S. patent for the combination therapy.

$MTVAMed

MetaVia completes phase 1 trial of liver disease drug DA-1726

MetaVia Inc. (MTVA) completed its Phase 1 trial for DA-1726, a drug for liver-related cardiometabolic diseases. The trial extended treatment to 24 weeks, showing a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss. Full data is expected in Q1 2027, with a Phase 2 study planned for late 2027. DA-1726 is a once-weekly subcutaneous treatment.

$MTVAMed

MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726

MetaVia Inc. (MTVA) completed its Phase 1 clinical trial for DA-1726, a novel GLP-1/glucagon dual-receptor agonist. The treatment period was extended to 24 weeks, with encouraging safety and tolerability data. Part 3B interim results showed a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss. Full data is expected in Q1 2027, with a Phase 2 study planned for H2 2027.

$NSRXMed

Nasus Pharma presents phase 2 data on intranasal epinephrine

Nasus Pharma (NYSE:NSRX) presented Phase 2 study data for NS002, an intranasal epinephrine powder, showing faster therapeutic threshold reach than autoinjectors. No serious adverse events were reported. The company plans a pivotal study by late 2026, with results expected in Q1 2027. NS002 is being developed as a needle-free alternative for anaphylaxis treatment.

$LUNGMed

Pulmonx Corporation: Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal System

Pulmonx Corporation (Nasdaq: LUNG) announced the publication of CONVERT Trial results for its AeriSeal System, showing 75.8% of patients with severe emphysema and collateral ventilation had successful treatment. The study suggests the system could enable subsequent treatment with Zephyr Valves, improving lung function and quality of life. Pulmonx is now conducting the CONVERT II Pivotal Trial to support a U.S. FDA Premarket Approval application for the AeriSeal System.